Cargando…

Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages

INTRODUCTION: M2 macrophages promote tissue repair and regeneration through various mechanisms including immunomodulation and scavenging of tissue debris. Delivering increased numbers of these cells to ischemic tissues may limit tissue injury and promote repair. Ixmyelocel-T is an expanded, autologo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ledford, Kelly J, Zeigler, Frank, Bartel, Ronnda L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029268/
https://www.ncbi.nlm.nih.gov/pubmed/24405629
http://dx.doi.org/10.1186/scrt345
_version_ 1782317182435196928
author Ledford, Kelly J
Zeigler, Frank
Bartel, Ronnda L
author_facet Ledford, Kelly J
Zeigler, Frank
Bartel, Ronnda L
author_sort Ledford, Kelly J
collection PubMed
description INTRODUCTION: M2 macrophages promote tissue repair and regeneration through various mechanisms including immunomodulation and scavenging of tissue debris. Delivering increased numbers of these cells to ischemic tissues may limit tissue injury and promote repair. Ixmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells (BMMNCs). The purpose of this study was to characterize further a unique expanded population of M2-like macrophages, generated in ixmyelocel-T therapy. METHODS: Approximately 50 ml of whole bone marrow was obtained from healthy donors and shipped overnight. BMMNCs were produced by using density-gradient separation and cultured for approximately 12 days to generate ixmyelocel-T. CD14(+) cells were isolated from ixmyelocel-T with positive selection for analysis. Cell-surface phenotype was examined with flow cytometry and immunofluorescence, and expression of cytokines and chemokines was analyzed with enzyme-linked immunosorbent assay (ELISA). Quantitative real-time PCR was used to analyze expression of genes in BMMNCs, ixmyelocel-T, the CD14(+) population from ixmyelocel-T, and M1 and M2 macrophages. Ixmyelocel-T was cultured with apoptotic BMMNCs, and then visualized under fluorescence microscopy to assess efferocytosis. RESULTS: Macrophages in ixmyelocel-T therapy expressed surface markers of M2 macrophages, CD206, and CD163. These cells were also found to express several M2 markers, and few to no M1 markers. After stimulation with lipopolysaccharide (LPS), they showed minimal secretion of the proinflammatory cytokines interleukin-12 (IL-12) and tumor necrosis factor alpha (TNF-α) compared with M1 and M2 macrophages. Ixmyelocel-T macrophages efficiently ingested apoptotic BMMNCs. CONCLUSIONS: Ixmyelocel-T therapy contains a unique population of M2-like macrophages that are characterized by expression of M2 markers, decreased secretion of proinflammatory cytokines after inflammatory stimuli, and efficient removal of apoptotic cells. This subpopulation of cells may have a potential role in tissue repair and regeneration.
format Online
Article
Text
id pubmed-4029268
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40292682014-05-22 Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages Ledford, Kelly J Zeigler, Frank Bartel, Ronnda L Stem Cell Res Ther Research INTRODUCTION: M2 macrophages promote tissue repair and regeneration through various mechanisms including immunomodulation and scavenging of tissue debris. Delivering increased numbers of these cells to ischemic tissues may limit tissue injury and promote repair. Ixmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells (BMMNCs). The purpose of this study was to characterize further a unique expanded population of M2-like macrophages, generated in ixmyelocel-T therapy. METHODS: Approximately 50 ml of whole bone marrow was obtained from healthy donors and shipped overnight. BMMNCs were produced by using density-gradient separation and cultured for approximately 12 days to generate ixmyelocel-T. CD14(+) cells were isolated from ixmyelocel-T with positive selection for analysis. Cell-surface phenotype was examined with flow cytometry and immunofluorescence, and expression of cytokines and chemokines was analyzed with enzyme-linked immunosorbent assay (ELISA). Quantitative real-time PCR was used to analyze expression of genes in BMMNCs, ixmyelocel-T, the CD14(+) population from ixmyelocel-T, and M1 and M2 macrophages. Ixmyelocel-T was cultured with apoptotic BMMNCs, and then visualized under fluorescence microscopy to assess efferocytosis. RESULTS: Macrophages in ixmyelocel-T therapy expressed surface markers of M2 macrophages, CD206, and CD163. These cells were also found to express several M2 markers, and few to no M1 markers. After stimulation with lipopolysaccharide (LPS), they showed minimal secretion of the proinflammatory cytokines interleukin-12 (IL-12) and tumor necrosis factor alpha (TNF-α) compared with M1 and M2 macrophages. Ixmyelocel-T macrophages efficiently ingested apoptotic BMMNCs. CONCLUSIONS: Ixmyelocel-T therapy contains a unique population of M2-like macrophages that are characterized by expression of M2 markers, decreased secretion of proinflammatory cytokines after inflammatory stimuli, and efficient removal of apoptotic cells. This subpopulation of cells may have a potential role in tissue repair and regeneration. BioMed Central 2013-11-01 /pmc/articles/PMC4029268/ /pubmed/24405629 http://dx.doi.org/10.1186/scrt345 Text en Copyright © 2013 Ledford et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ledford, Kelly J
Zeigler, Frank
Bartel, Ronnda L
Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages
title Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages
title_full Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages
title_fullStr Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages
title_full_unstemmed Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages
title_short Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages
title_sort ixmyelocel-t, an expanded multicellular therapy, contains a unique population of m2-like macrophages
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029268/
https://www.ncbi.nlm.nih.gov/pubmed/24405629
http://dx.doi.org/10.1186/scrt345
work_keys_str_mv AT ledfordkellyj ixmyeloceltanexpandedmulticellulartherapycontainsauniquepopulationofm2likemacrophages
AT zeiglerfrank ixmyeloceltanexpandedmulticellulartherapycontainsauniquepopulationofm2likemacrophages
AT bartelronndal ixmyeloceltanexpandedmulticellulartherapycontainsauniquepopulationofm2likemacrophages